EyePoint Pharma 
Welcome,         Profile    Billing    Logout  
 6 Products   5 Diseases   6 Products   16 Trials   639 News 


«123456»
  • ||||||||||  Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
    Journal, Monotherapy:  Efficacy of the Fluocinolone Acetonide (Yutiq) Intravitreal Implant as Monotherapy for Uveitis. (Pubmed Central) -  Jul 7, 2022   
    The fluocinolone acetonide implant may not suffice as monotherapy for all patients with uveitis, but it may be effective as an adjunctive treatment. We propose a clinical workflow for the selection and treatment of patients who may benefit from it.
  • ||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    Review, Journal, Real-world evidence:  Real-World Experience with Intracapsular Administration of Dexamethasone Intraocular Suspension 9% for Control of Postoperative Inflammation. (Pubmed Central) -  Jun 28, 2022   
    DEXYCU (dexamethasone intraocular suspension) 9% is the first and only intraocular corticosteroid FDA-approved for postoperative inflammation, whose sustained-release formulation provides a high initial release of drug, followed by a gradual tapering...This technique also minimizes contact with metabolically active tissues such as the corneal endothelium, iris, and ciliary body. In this paper, we review the available literature on dexamethasone intraocular suspension and summarize surgeons' consensus on best practices for intracapsular administration.
  • ||||||||||  Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma, Ozurdex (dexamethasone intravitreal implant) / AbbVie, Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Long-term Dose-controllable Drug Delivery Implant (F0147) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_4702;    
    The drug delivery system was safe and stable against leakage for 6 months. The light-activated drug delivery system that we developed will provide tightly-controlled release without burst release.
  • ||||||||||  dexamethasone / Generic mfg.
    Anterior Chamber Versus Intravitreal Administration of Dexamethasone 9% Suspension in Cataract Patients with and without Glaucoma (WEWCC - Level 1, 143C) -  Apr 26, 2022 - Abstract #ASCRSASOA2022ASCRS-ASOA_1480;    
    MethodsRetrospective data were collected from patients who received dexamethasone 9% suspension (DEXYCU®; EyePoint Pharmaceuticals) either via anterior chamber administration (on-label) or intravitreal injection (off-label) after cataract surgery, with/without minimally invasive glaucoma surgery (MIGS)...All patients were given intracameral moxifloxacin at the time of surgery...1 patient in the IVD required rescue medications compared to 8 patients in the ACD group (p<0.01). Conclusion Administration of IVD or ACD does not impede the intraocular pressure reduction produced by cataract surgery combined with MIGS.
  • ||||||||||  Clinical, Review, Journal:  A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation. (Pubmed Central) -  Apr 9, 2022   
    Nanoparticles and ocular iontophoresis form the next wave of DDS that have the potential to replace topical steroids eye-drops as the treatment of choice for anterior segment inflammation. With the current relentless pace of ophthalmic drug delivery research, the pursuit of a new standard of treatment that eliminates the problems of low bioavailability and patient compliance may soon be realised.
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Retrospective data, Journal:  Effect of Extended Release Steroid Implants on the Contralateral Eye. (Pubmed Central) -  Mar 30, 2022   
    With the current relentless pace of ophthalmic drug delivery research, the pursuit of a new standard of treatment that eliminates the problems of low bioavailability and patient compliance may soon be realised. In this study there was no statistically significant effect on CME of contralateral intravitreal corticosteroid implants.
  • ||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    Clinical, Journal:  Iris Atrophy After Administration of Intracameral Dexycu in Routine Cataract Surgery: A Case Series. (Pubmed Central) -  Mar 19, 2022   
    None of the five eyes treated with traditional anti-inflammatory drops developed iris atrophy. The Dexycu intraocular dexamethasone implant was designed to mitigate postoperative inflammation and reduce need for topical therapy but may be associated with other potential adverse effects that warrant consideration.
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Review, Journal:  The Use of Sustained Release Intravitreal Steroid Implants in Non-Infectious Uveitis Affecting the Posterior Segment of the Eye. (Pubmed Central) -  Feb 1, 2022   
    In particular, they have provided an alternative mode of treatment for patients who do not wish to be systemically immunosuppressed, or in whom such immunosuppression is less desirable, such as those with unilateral disease or those with concurrent illnesses such as diabetes mellitus, renal disease or osteoporosis that are negatively impacted by systemic corticosteroids or other immunosuppressive agents. In this article, we review the evidence for the use of the major licensed corticosteroid implants and assess the advantages and disadvantages of each.
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Trial completion:  PALADIN: Phase 4 IOP Signals Associated With ILUVIEN® (clinicaltrials.gov) -  Jan 11, 2022   
    P4,  N=153, Completed, 
    This improvement in macular perfusion may be associated with corticosteroid-related beneficial effects on leukostasis. Active, not recruiting --> Completed
  • ||||||||||  Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
    Enrollment open:  Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI) (clinicaltrials.gov) -  Dec 3, 2021   
    P3,  N=60, Recruiting, 
    Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jan 2023 --> Jan 2024 Not yet recruiting --> Recruiting
  • ||||||||||  Triesence (triamcinolone acetonide injectable suspension) / Novartis, Kenalog-40 (triamcinolone acetonide injection suspension) / BMS, Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Journal:  BILATERAL INTRAVITREAL 0.19-MG FLUOCINOLONE ACETONIDE IMPLANT FOR PERSISTENT NONDIABETIC CYSTOID MACULAR EDEMA AFTER VITRECTOMY. (Pubmed Central) -  Oct 31, 2021   
    The FAc implant was a safe option for resolving macular edema secondary to NIU-PS. The intravitreal 0.19-mg fluocinolone acetonide implant is an effective and potentially safe off-label therapeutic option for persistent nondiabetic cystoid macular edema after vitrectomy.
  • ||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    V06 - The Capsular Bag: A New Site for Drug Delivery (Morial Convention Center) -  Oct 20, 2021 - Abstract #AAO2021AAO_2103;    
    This study evaluating the injection of Dexycu into a new location, the capsular bag, proved very promising. It was conducted independently and without support of the manufacturer.
  • ||||||||||  Dextenza (dexamethasone punctal plug) / Ocular Therap, Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    Utilization and Cost-Analysis of Novel Dropless Steroid Alternatives for Cataract Surgery Among Medicare Beneficiaries (Morial Convention Center) -  Oct 20, 2021 - Abstract #AAO2021AAO_1659;    
    Conclusion Dropless dexamethasone delivery technologies address patient inconvenience and poor compliance but entail disproportionately high costs compared to traditional steroid drops. This may explain the low adoption rates of these new drug delivery technologies, despite their pass-through status.